量子生物制药公司改变管理层, 给予奖金, 授权债务结算到2024年. Quantum BioPharma changes management and grants bonuses, authorizes debt settlements for 2024.
量子生物制药公司是一家专门研究神经降解和代谢障碍创新解决方案的生物制药公司,它宣布了管理变革,Donal Carroll作为CFO, Nathan Coyle担任主计长,Jason Sawyer担任财务和并购负责人。 Quantum BioPharma, a biopharmaceutical company specializing in innovative solutions for neurodegenerative and metabolic disorders, has announced management changes, with Donal Carroll as CFO, Nathan Coyle as Controller, and Jason Sawyer heading Finance and M&A. 公司取消了购买股票的选择权,授予限制股票单位 (RSU),并授权每名官员获得45万美元的奖金,每股5.44美元. The company has cancelled options to purchase shares, granted restricted share units (RSUs), and authorized $450,000 bonuses per officer, to be paid in shares at $5.44 each. 涉及官员安东尼·杜尔卡茨、泽斯汉·赛义德和多纳尔·卡罗尔的债务结算计划于2024年9月进行。 Debt settlements, involving officers Anthony Durkacz, Zeeshan Saeed, and Donal Carroll, are planned for September 2024.